Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Updates in Alzheimer’s treatment: the potential of NSC001

Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses a Phase Ib investigating NSC001 as a treatment for Alzheimer’s disease (AD). NSC001 targets the cholinergic system, considered to be one of the first systems that shows degeneration in AD. Unlike traditional cholinesterase inhibitors, NSC001 is an M1 selective and specific orthosteric partial agonist which means it does not depend on endogenous acetylcholine. The trial enrolled 60 healthy aged individuals who were randomized to receive placebo or one of four doses of NSC001. Results showed that NSC001 crossed the blood-brain barrier and was well tolerated. EEG data showed a significant increase in alpha slow-wave index, suggesting target engagement. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.